News Phase 3 trial win sets up rare disease drug filing for CSL VANUGUARD trial of garadacimab in HAE sets up a pursuit of Takeda's fast-growing Takhyzro.
News NICE backs Roche's non-Hodgkin lymphoma drug Columvi NICE backs NHS use of Roche's Columvi as a second-line therapy for a form of non-Hodgkin lymphoma affecting thousands of people in the UK each year.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
